These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. Choo JM; Abell GCJ; Thomson R; Morgan L; Waterer G; Gordon DL; Taylor SL; Leong LEX; Wesselingh SL; Burr LD; Rogers GB mSphere; 2018 Apr; 3(2):. PubMed ID: 29669883 [TBL] [Abstract][Full Text] [Related]
4. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Dicker AJ; Lonergan M; Keir HR; Smith AH; Pollock J; Finch S; Cassidy AJ; Huang JTJ; Chalmers JD Lancet Respir Med; 2021 Aug; 9(8):885-896. PubMed ID: 33961805 [TBL] [Abstract][Full Text] [Related]
5. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Tunney MM; Einarsson GG; Wei L; Drain M; Klem ER; Cardwell C; Ennis M; Boucher RC; Wolfgang MC; Elborn JS Am J Respir Crit Care Med; 2013 May; 187(10):1118-26. PubMed ID: 23348972 [TBL] [Abstract][Full Text] [Related]
6. Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis. Byun MK; Chang J; Kim HJ; Jeong SH PLoS One; 2017; 12(8):e0183553. PubMed ID: 28829833 [TBL] [Abstract][Full Text] [Related]
7. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200 [TBL] [Abstract][Full Text] [Related]
8. Differential airway resistome and its correlations with clinical characteristics in Haemophilus- or Pseudomonas-predominant microbial subtypes of bronchiectasis. Yi XZ; Yang JH; Huang Y; Han XR; Li HM; Cen LJ; Lin ZH; Pan CX; Wang Z; Guan WJ Respir Res; 2023 Nov; 24(1):264. PubMed ID: 37919749 [TBL] [Abstract][Full Text] [Related]
9. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Rogers GB; Zain NM; Bruce KD; Burr LD; Chen AC; Rivett DW; McGuckin MA; Serisier DJ Ann Am Thorac Soc; 2014 May; 11(4):496-503. PubMed ID: 24592925 [TBL] [Abstract][Full Text] [Related]
10. Infection and the microbiome in bronchiectasis. Mac Aogáin M; Dicker AJ; Mertsch P; Chotirmall SH Eur Respir Rev; 2024 Jul; 33(173):. PubMed ID: 38960615 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Grimwood K; Bell SC; Chang AB Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1277-96. PubMed ID: 25156239 [TBL] [Abstract][Full Text] [Related]
13. Dynamic Upper and Lower Airway Microbiotas in Paediatric Bronchiectasis Exacerbations: A Pilot Study. Broderick DTJ; Regtien T; Ainsworth A; Taylor MW; Pillarisetti N Front Cell Infect Microbiol; 2021; 11():773496. PubMed ID: 35141165 [TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Taylor SL; Rogers GB; Chen AC; Burr LD; McGuckin MA; Serisier DJ Ann Am Thorac Soc; 2015 May; 12(5):701-7. PubMed ID: 25679336 [TBL] [Abstract][Full Text] [Related]
15. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis. Narayana JK; Aliberti S; Mac Aogáin M; Jaggi TK; Ali NABM; Ivan FX; Cheng HS; Yip YS; Vos MIG; Low ZS; Lee JXT; Amati F; Gramegna A; Wong SH; Sung JJY; Tan NS; Tsaneva-Atanasova K; Blasi F; Chotirmall SH Am J Respir Crit Care Med; 2023 Apr; 207(7):908-920. PubMed ID: 36288294 [No Abstract] [Full Text] [Related]
16. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Rogers GB; van der Gast CJ; Cuthbertson L; Thomson SK; Bruce KD; Martin ML; Serisier DJ Thorax; 2013 Aug; 68(8):731-7. PubMed ID: 23564400 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Mayhew D; Devos N; Lambert C; Brown JR; Clarke SC; Kim VL; Magid-Slav M; Miller BE; Ostridge KK; Patel R; Sathe G; Simola DF; Staples KJ; Sung R; Tal-Singer R; Tuck AC; Van Horn S; Weynants V; Williams NP; Devaster JM; Wilkinson TMA; Thorax; 2018 May; 73(5):422-430. PubMed ID: 29386298 [TBL] [Abstract][Full Text] [Related]
18. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. Chandrasekaran R; Mac Aogáin M; Chalmers JD; Elborn SJ; Chotirmall SH BMC Pulm Med; 2018 May; 18(1):83. PubMed ID: 29788932 [TBL] [Abstract][Full Text] [Related]
19. The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap. Tiew PY; Jaggi TK; Chan LLY; Chotirmall SH Clin Respir J; 2021 Feb; 15(2):123-133. PubMed ID: 33063421 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the pulmonary microbiome in healthy and diseased pigs. Li Z; Wang X; Di D; Pan R; Gao Y; Xiao C; Li B; Wei J; Liu K; Qiu Y; Ma Z Mol Genet Genomics; 2021 Jan; 296(1):21-31. PubMed ID: 32944788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]